Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVV-01 Administered Intravenously and Intratumorally in Combination With AK112 in Patients With Advanced Solid Tumors
NCT07650825Phase 1Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2026
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of OVV-01 in solid tumor (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Dose-Limiting Toxicity at 21 days and Incidence of Adverse Events at 24 months. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
OVV-01
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07650825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07650825.